Mark Talamonti to Cell Line, Tumor
This is a "connection" page, showing publications Mark Talamonti has written about Cell Line, Tumor.
Connection Strength
0.129
-
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272.
Score: 0.026
-
Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Gut. 2012 Oct; 61(10):1454-64.
Score: 0.016
-
Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells. Anticancer Drugs. 2007 Jun; 18(5):535-41.
Score: 0.012
-
Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. J Surg Res. 2007 Apr; 138(2):163-9.
Score: 0.012
-
Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol Cancer. 2006 Dec 29; 5:76.
Score: 0.011
-
On the mechanisms of 12-O-tetradecanoylphorbol-13-acetate-induced growth arrest in pancreatic cancer cells. Pancreas. 2006 Aug; 33(2):148-55.
Score: 0.011
-
LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun. 2005 Sep 30; 335(3):949-56.
Score: 0.011
-
Identification and in silico characterization of a novel gene: TPA induced trans-membrane protein. Biochem Biophys Res Commun. 2005 Apr 08; 329(2):755-64.
Score: 0.010
-
LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. Neoplasia. 2005 Apr; 7(4):417-25.
Score: 0.010
-
Pancreatic cancer stimulates pancreatic stellate cell proliferation and TIMP-1 production through the MAP kinase pathway. Biochem Biophys Res Commun. 2004 Oct 29; 323(4):1241-5.
Score: 0.010